Diversify in foreign currency, while enjoying the simple convenience of an EverBank WorldCurrency CD or money market account. Step 1, choose your account type. Step 2, choose from our wide range of currencies, which includes all the major ones and some from emerging markets. It's that simple. Apply now.
CEOs: Put Your Money Where Your Mouth Is
by Robert Williams, Publisher
Wednesday, October 21, 2009
It’s well documented. Insider buying is a terrific way to gauge a stock’s investment appeal. (Investment legends, like Peter Lynch, have long sung the praises of insider buying.)
I mean, can you get a better vote of confidence from a CEO than one that’s willing to open his own checkbook for shares?
Probably not.
That being said, such buying alone should never warrant entry. Other factors are always “in play,” too.
For example, what warrants a “significant” buy on behalf of an insider? Well, with access to the right information, you can track the amount an insider antes up relative to his salary.
You’d also be interested in knowing whether the “buy” is merely an exercising of stock options, or a genuine purchase of shares.
My point is that all this (and more) matters.
Fortunately, Alexander Green tracks insider trading, both buying and selling, religiously for us here at Investment U. And he knows better than anyone whether a stock whose shares are under accumulation by insiders really warrants our hard-earned investment dollars.
In fact, subscribers to his Insider Alert have closed out winning positions on 15 out of 20 stocks this year. So class is officially in session. Read more on his article about insider selling.
Ahead of the tape,
Robert Williams
- Insider Selling: How to Profit From The Insiders’ Unfair Advantage
- What Corporate Insiders Are Telling Us
- What to Make of the Rising “Fear Index”
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
In addition to once being a full-time trader of equities and equity derivatives, Robert Williams has also served as the lead financial analyst for a Forbes top-50 private corporation and an analyst for the endowment of a major academic institution.
Investment U RSS Feed